Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV (Q26783973)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV	scientific article

Statements

scholarly article

0 references

2 references

29 May 2020

16 December 2020

systematic review

1 reference

PubMed publication ID

1 reference

PubMed publication ID

Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV (English)

0 references

uterine cervix neoplasm

1 reference

16 December 2020

Alphapapillomavirus

1 reference

3 November 2019

1 reference

PubMed publication ID

Papillomavirus infections

1 reference

16 December 2020

systematic review

1 reference

based on heuristic

inferred from title

Roberto D'Amico

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Simona Di Mario

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Vittorio Basevi

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Pier Luigi Lopalco

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Nicola Magrini

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

0 references

publication date

25 August 2015

8 references

13 March 2019

14 March 2019

23 March 2019

3 April 2019

20 June 2019

21 October 2019

3 November 2019

16 December 2020

Journal of Immunology Research

10 references

13 March 2019

14 March 2019

23 March 2019

3 April 2019

20 June 2019

21 October 2019

3 November 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

16 December 2020

2015

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

435141

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

copyright license

Creative Commons Attribution 3.0 Unported

9 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

14 March 2019

Europe PubMed Central

23 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

20 June 2019

Europe PubMed Central

21 October 2019

Europe PubMed Central

3 November 2019

Europe PubMed Central

29 May 2020

Europe PubMed Central

16 December 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

7 April 2017

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

7 April 2017

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

7 April 2017

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

7 April 2017

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

7 April 2017

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

25 May 2017

Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Getting more generous with the truth: clinical trial reporting in 2013 and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

From desire to disease: human papillomavirus (HPV) and the medicalization of nascent female sexuality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Prevalence and risk factors of HPV infection among women from various provinces of the world

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

The known unknowns of HPV natural history

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Human papillomavirus: science and technologies for the elimination of cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

The Statistics of Anti-typhoid and Anti-cholera Inoculations, and the Interpretation of such Statistics in general

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Advances in prevention of cervical cancer and other human papillomavirus-related diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Worldwide burden of gynaecological cancer: the size of the problem

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

The promise of global cervical-cancer prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 September 2017

Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

31 May 2018

Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

31 May 2018

Prevalence and risk factors of high-risk human papillomavirus in female sex workers in Spain: differences by geographical origin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

31 May 2018

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

31 May 2018

Epidemiology of Genital Human Papillomavirus Infection

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Clinical trial data for all drugs in current use.

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available?

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F435141

21 January 2018

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562171

28 November 2018

UK will use Gardasil in its HPV vaccination programme from next September

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human Papillomavirus Vaccination — Reasons for Caution

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HPV-beyond cervical cancer (online resource center)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The need to promote independent research on drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/26380321

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2015/435141

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

release_6epn4skv5ffdbcjmr2lic35sb4

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26380321%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26783973&oldid=1951672342"